The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
BJD, 2023.
Oras A. Alabas, Kayleigh J. Mason, Zenas Z.N. Yiu, Richard B. Warren, Nick Dand, Jonathan N.W.N. Barker, Catherine H. Smith, Christopher E.M. Grifï¬ths, the BADBIR and BSTOP study group.
Read publication: BJD
Related
Characteristics of "super responders" and "super nonresponders" to first biologic monotherapy for ps...
Uptake of tumour necrosis factor - alpha inhibitor biosimilars for psoriasis: A drug utilisation stu...
Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective c...
0 Comments